KR20210008840A - 키메라 노치 수용체 - Google Patents

키메라 노치 수용체 Download PDF

Info

Publication number
KR20210008840A
KR20210008840A KR1020207032411A KR20207032411A KR20210008840A KR 20210008840 A KR20210008840 A KR 20210008840A KR 1020207032411 A KR1020207032411 A KR 1020207032411A KR 20207032411 A KR20207032411 A KR 20207032411A KR 20210008840 A KR20210008840 A KR 20210008840A
Authority
KR
South Korea
Prior art keywords
cell
cells
gly
cys
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020207032411A
Other languages
English (en)
Korean (ko)
Inventor
더크 암센
Original Assignee
스티흐팅 산퀸 불드포르지닝
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티흐팅 산퀸 불드포르지닝 filed Critical 스티흐팅 산퀸 불드포르지닝
Publication of KR20210008840A publication Critical patent/KR20210008840A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
KR1020207032411A 2018-04-10 2019-04-10 키메라 노치 수용체 Abandoned KR20210008840A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18166498.8 2018-04-10
EP18166498 2018-04-10
PCT/NL2019/050212 WO2019199165A1 (en) 2018-04-10 2019-04-10 Chimeric notch receptors

Publications (1)

Publication Number Publication Date
KR20210008840A true KR20210008840A (ko) 2021-01-25

Family

ID=62063276

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207032411A Abandoned KR20210008840A (ko) 2018-04-10 2019-04-10 키메라 노치 수용체

Country Status (9)

Country Link
US (1) US20210139556A1 (https=)
EP (1) EP3774867A1 (https=)
JP (1) JP7562417B2 (https=)
KR (1) KR20210008840A (https=)
CN (1) CN112243442A (https=)
AU (1) AU2019252878B2 (https=)
CA (1) CA3096812A1 (https=)
IL (1) IL277859A (https=)
WO (1) WO2019199165A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116790647B (zh) * 2023-02-06 2024-04-16 森瑞斯生物科技(深圳)有限公司 一种低背景、高信号强度的2-吡咯烷酮生物传感器及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047878A1 (en) * 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
CN104402998A (zh) * 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
SG191039A1 (en) * 2010-12-15 2013-08-30 Wyeth Llc Anti-notch1 antibodies
EP2970479B1 (en) * 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
BR112016028537A2 (pt) * 2014-06-04 2017-08-22 Hutchinson Fred Cancer Res expansão e enxerto de células-tronco utilizando agonistas de notch 1 e/ou de notch 2
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
WO2016138034A1 (en) * 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
WO2017123559A2 (en) * 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
JP7500195B2 (ja) * 2016-08-23 2024-06-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法
US11325957B2 (en) * 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Amsen, D., Antov, A., Jankovic, D., Sher, A., Radtke, F., Souabni, A., Busslinger, M., McCright, B., Gridley, T., Flavell, R. A.가 2007년에 저술한 "Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch"의 타이틀을 가지는 자료로서, Immunity 27, 89-99를 통해 발간한 자료.
Amsen, D., Blander, J. M., Lee, G. R., Tanigaki, K., Honjo, T., Flavell, R. A.가 2004년에 저술한 "Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells"의 타이틀을 가지는 자료로서, Cell 117, 515-526를 통해 발간된 자료.
Anders, S., McCarthy, D. J., Chen, Y., Okoniewski, M., Smyth, G. K., Huber, W., Robinson, M. D.가 2013년에 저술한 "Count-based differential expression analysis of RNA sequencing data using R and Bioconductor"의 타이틀을 가지는 자료로서, Nat Protoc 8, 1765-1786을 통해 발간된 자료.
Backer, R. A., Helbig, C., Gentek, R., Kent, A., Laidlaw, B. J., Dominguez, C. X., de Souza, Y. S., van Trierum, S. E., van Beek, R., Rimmelzwaan, G. F., ten Brinke, A., Willemsen, A. M., van Kampen, A. H., Kaech, S. M., Blander, J. M., van Gisbergen, K., Amsen, D.가 2014년에 저술한 "A central role for Notch in effector CD8(+) T cell differentiation"의 타이틀을 가지는 자료로서, Nat Immunol 15, 1143-1151를 통해 발간된 자료.
Belz, G. T., Xie, W., Altman, J. D., Doherty, P. C.가 2000년에 저술한 "A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge"의 타이틀을 가지는 자료로서, J Virol 74, 3486-3493를 통해 발간된 자료.
Gentek R, Munneke JM, Helbig C, Blom B, Hazenberg MD, Spits H, Amsen D.가 저술한 "Modulation of Signal Strength Switches Notch from an Inducer of T Cells to an Inducer of ILC2"의 타이틀을 가지는 자료로서, Front Immunol. 2013 Oct 22;4:334를 통해 발간된 자료.
Helbig, C., Gentek, R., Backer, R. A., de Souza, Y., Derks, I. A., Eldering, E., Wagner, K., Jankovic, D., Gridley, T., Moerland, P. D., Flavell, R. A., Amsen, D.가 2012년에 저술한 "Notch controls the magnitude of T helper cell responses by promoting cellular longevity"의 타이틀을 가지는 자료로서, Proceedings of the National Academy of Sciences of the United States of America 109, 9041-9046를 통해 발간된 자료.
Kochenderfer JN. et al가 저술한 "Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor"의 타이틀을 가지는 자료로서, J Immunother. 2009 Sep; 32(7): 689-702를 통해 발간된 자료.
Legrand N. et al가 저술한 "Functional CD47/signal regulatory protein alpha (SIRPα) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo"의 타이틀을 가지는 자료로서, J Immunol 2009; 183:7645-7655를 통해 발간된 자료.
Ma, J. S., Kim, J. Y., Kazane, S. A., Choi, S. H., Yun, H. Y., Kim, M. S., Rodgers, D. T., Pugh, H. M., Singer, O., Sun, S. B., Fonslow, B. R., Kochenderfer, J. N., Wright, T. M., Schultz, P. G., Young, T. S., Kim, C. H., Cao, Y.가 2016년에 저술한 "Versatile strategy for controlling the specificity and activity of engineered T cells"의 타이틀을 가지는 자료로서, Proc Natl Acad Sci U S A 113, E450-458을 통해 발간된 자료.
Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., Lim, W. A.가 2016년 저술한 "Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors"의 타이틀을 가지는 자료로서, Cell 164, 780-791를 통해 발간된 자료.
Mueller, S. N., Langley, W. A., Carnero, E., Garcia-Sastre, A., Ahmed, R.가 2010년에 저술한 "Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses"의 타이틀을 가지는 자료로서, J Virol 84, 1847-1855를 통해 발간된 자료.
Nam, Y., Sliz, P., Pear, W. S., Aster, J. C., Blacklow, S. C.가 2007년에 저술한 "Cooperative assembly of higher-order Notch complexes functions as a switch to induce transcription"의 타이틀을 가지는 자료로서, Proceedings of the National Academy of Sciences of the United States of America 104, 2103-2108를 통해 발간된 자료.
Nicholson, I.C. et al가 저술한 "Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma"의 타이틀을 가지는 자료로서, Molecular Immunology 1997;34:1157-1165를 통해 발간된 자료.
Palmer, D. F., Dowdle, W. R., Coleman, M. T., Schild, G. C.가 1975년에 저술한 "Advanced laboratory techniques for influenza diagnosis: procedural guide"의 타이틀을 가지는 자료로서, Haemagglutination inhibition test. in Atlanta: US Department of Health, Education and Welfare, Public Health Service, US Department of Health, Education and Welfare, Public Health Service. pp 25-62를 통해 발간된 자료.
Rodgers, D. T., Mazagova, M., Hampton, E. N., Cao, Y., Ramadoss, N. S., Hardy, I. R., Schulman, A., Du, J., Wang, F., Singer, O., Ma, J., Nunez, V., Shen, J., Woods, A. K., Wright, T. M., Schultz, P. G., Kim, C. H., Young, T. S.가 2016년에 저술한 "Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies"의 타이틀을 가지는 자료로서, Proc Natl Acad Sci U S A 113, E459-468를 통해 발간된 자료.
Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., Lim, W. A.가 2016년에 저술한 "Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits"의 타이틀을 가지는 자료로서, Cell 164, 770-779를 통해 발간된 자료.
Topham, D. J., Castrucci, M. R., Wingo, F. S., Belz, G. T., Doherty, P. C.가 2001년에 저술한 "The role of antigen in the localization of naive, acutely activated, and memory CD8(+) T cells to the lung during influenza pneumonia"의 타이틀을 가지는 자료로서, J Immunol 167, 6983-6990를 통해 발간된 자료.
Van der Sluijs, K. F., van Elden, L. J., Nijhuis, M., Schuurman, R., Pater, J. M., Florquin, S., Goldman, M., Jansen, H. M., Lutter, R., van der Poll, T.가 2004년에 저술한 "IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection"의 타이틀을 가지는 자료로서, J Immunol 172, 7603-7609를 통해 발간된 자료.
van Lent AU, et al가 저술한 "IL-7 enhances thymic human T cell development in "human immune system" Rag2-/-IL-2Rgammac-/- mice without affecting peripheral T cell homeostasis"의 타이틀을 가지는 자료로서, J Immunol. 2009;183:7645-7655를 통해 발간된 자료.
Wherry, E. J., Kurachi, M.가 2015년에 저술한 "Molecular and cellular insights into T cell exhaustion"의 타이틀을 가지는 자료로서, Nat Rev Immunol 15, 486-499를 통해 발간된 자료.
Young, M. D., Wakefield, M. J., Smyth, G. K., Oshlack, A.가 2010년에 저술한 "Gene ontology analysis for RNA-seq: accounting for selection bias"의 타이틀을 가지는 자료로서, Genome biology 11, R14를 통해 발간된 자료.

Also Published As

Publication number Publication date
AU2019252878B2 (en) 2024-02-22
IL277859A (en) 2020-11-30
US20210139556A1 (en) 2021-05-13
CN112243442A (zh) 2021-01-19
JP7562417B2 (ja) 2024-10-07
WO2019199165A1 (en) 2019-10-17
AU2019252878A1 (en) 2020-11-26
EP3774867A1 (en) 2021-02-17
CA3096812A1 (en) 2019-10-17
JP2021520813A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
JP7262535B2 (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US12565535B2 (en) Chimeric antigen receptors targeted to PSCA
JP7217970B2 (ja) 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
JP7228900B2 (ja) 操作されたナチュラルキラー細胞およびその使用
Ang et al. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis
ES2835269T5 (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
ES2959683T3 (es) Células manipuladas para terapia celular adoptiva
TWI823829B (zh) 靶向血液惡性腫瘤之嵌合抗原受體（ｃａｒ），其組合物及使用方法
RU2708311C2 (ru) Химерные антигенные рецепторы с mnd-промотором
ES2784537T3 (es) Inmunorreceptores y epítopos de células T específicos de Claudina-6
CN111247242A (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
US20140302608A1 (en) Modified Effector Cell (or Chimeric Receptor) for Treating Disialoganglioside GD2-Expressing Neoplasia
KR20200087133A (ko) 변형된 car-t
US20230149460A1 (en) Methods for generating engineered memory-like nk cells and compositions thereof
CN115916963A (zh) 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
JP7057975B2 (ja) 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球
JP7562417B2 (ja) キメラノッチ受容体
RU2777284C2 (ru) Сконструированные клетки - естественные киллеры и их применение
WO2025250011A1 (en) Treatment for cancer
CN117529333A (zh) 对先前进行过干细胞移植的患者的t细胞疗法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-NAP-PC1904 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904

U14 Designation fee not paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U14-OTH-PC1904 (AS PROVIDED BY THE NATIONAL OFFICE)